Ursolive capsules 250mg, 100pcs

Composition

Active ingredient:

ursodeoxycholic acid 250 mg.

Auxiliary substances:

Ingredients: lactulose,

microcrystalline cellulose,

low-molecular-weight povidone,

magnesium stearate,

talc.

Pharmacological action

Ursoliv Is a Hepatoprotector.

The active ingredient is ursodeoxycholic acid.

 The drug has cholelitolytic, choleretic, hypocholesterolemic, hypolipidemic and immunostimulating effects.

Scientific studies have shown that the Active ingredient reduces the hepatotoxicity of bile acid salts, has a pronounced protective effect on liver cells.

The drug Ursoliv reduces cholesterol levels by reducing its adsorption in the intestinal lumen.

 The drug is able to destroy cholesterol-containing gallstones in the gallbladder.

The Active ingredient stimulates the formation and discharge of bile, as well as the elimination of toxic acids through the intestinal lumen.

Ursodeoxycholic acid enhances the secretion of gastric and pancreatic juice, increases lipase activity, and has a hypolipidemic effect.

By reducing the number of eosinophils, suppressing interleukin production, and reducing the expression of antigens, an immunomodulatory effect is achieved.

Indications

• Cholelithiasis
• Biliary reflux-gastritis.
• Primary biliary cirrhosis in the absence of signs of decompensation (symptomatic therapy);
• Dissolution of small and medium-sized cholesterol stones with a functioning gallbladder;

Use during pregnancy and lactation

Contraindicated.

Contraindications

• acute cholecystitis
• cirrhosis of the liver
• severe renal and / or hepatic dysfunction.

Side effects

Allergic reactions.

Interaction

When used together, antacids containing aluminum and ion-exchange resins (colestyramine) reduce the absorption of UDCA.

When used concomitantly, lipid-lowering medications (especially clofibrate), estrogens, neomycin, or progestogens (oral contraceptives) increase bile saturation with cholesterol and may reduce the ability of ursodeoxycholic acid to dissolve cholesterol gallstones.

When used concomitantly, UDCA may increase cyclosporine absorption.

How to take, course of use and dosage

The drug is prescribed inside.

When dissolving cholesterol gallstones, capsules are taken in the evening, before going to bed, without chewing and with a small amount of liquid.

The dose is 10 mg / kg of body weight daily, which corresponds to: 2 capsules of Ursoliv in patients with a body weight of up to 60 kg; 3 capsules – in patients with a body weight of up to 80 kg; 4 capsules – in patients with a body weight of up to 100 kg; 5 capsules – in patients with a body weight of over 100 kg. The duration of treatment is 6-12 months.

To prevent the re-formation of stones, it is recommended to take the drug for several more months after the dissolution of the stones.

In the symptomatic treatment of primary biliary cirrhosis, the daily dose depends on body weight and ranges from 2 to 6 capsules (from 10 to 15 mg/kg of body weight).

The drug is taken with food, washed down with a sufficient amount of water.

For the treatment of biliary reflux gastritis,1 capsule is prescribed 1 time/day before bedtime. The course of treatment is from 10-14 days to 6 months, if necessary-up to 2 years.

Special instructions

For the dissolution of UDCA gallstones, concretions should be cholesterol (not radiopaque), no more than 15-20 mm in size. At the same time, the gallbladder should remain functional, and the patency of the cystic and common bile ducts should be preserved.

When prescribed for the purpose of dissolving gallstones, it is necessary to conduct a biochemical blood test monthly, and then every 3 months to determine the activity of” liver ” transaminases, alkaline phosphatase, gamma-glutamyltranspeptidase, as well as the concentration of bilirubin.

 If elevated indicators persist, the drug should be discontinued. To monitor the effectiveness of treatment, it is recommended to conduct an X-ray and ultrasound examination of the biliary tract every 6 months.

If calcification of gallstones, impaired contractility of the gallbladder or frequent attacks of biliary colic, treatment should be discontinued.

If there is no partial dissolution of the calculi within 6-12 months after the start of therapy, it is unlikely that the treatment will be effective.

Detection of an unvisualized gallbladder during treatment is an indication that the calculus has not completely dissolved and treatment should be discontinued.

After complete dissolution of the stones, to avoid relapses, it is recommended to continue using ursodeoxycholic acid for 3 months.

The drug does not adversely affect the ability to drive vehicles and/or other mechanisms.

Form of production

Capsules

Storage conditions

Store in a dry place protected from light at a temperature not exceeding 25 ° C.

Shelf

life is 4 years.

Active ingredient

Ursodeoxycholic acid

Conditions of release from pharmacies

By prescription

Dosage form

Capsules